Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
The Summers Value Fund returned -1.8% net in Q2 2025, underperforming the Russell 2000 which gained 8.5%, bringing year-to-date performance to -12.8%. Since inception in...
— Andrew Summers
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Journey Medical
Journey Medical represents a compelling specialty pharmaceutical play backed by its recent FDA approval of Emrosi for treating Rosacea. Emrosi has shown...
Journey Medical Corporation, despite a challenging year-to-date performance, shows promising signs of recovery and growth. The company's Q2...